MedTrace Logo

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)

NCT00980681 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-05-26

Study results available
· View outcomes & findings →

Summary

The study will evaluate the efficacy and safety of Dotarem enhanced MRA compared to TOF MRA in patients suffering from renal arterial disease.

Conditions

  • Renal Disease

Interventions

DRUG

Dotarem

Each subject will receive one injection of Dotarem 0.2ml/kg

OTHER

Time of Flight

Each subject will undergo a TOF MRA

Sponsors & Collaborators

  • Guerbet

    lead INDUSTRY

Principal Investigators

  • Pierre DESCHE, MD · Guerbet

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00980681 on ClinicalTrials.gov